...
首页> 外文期刊>Organogenesis >Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. [Review]
【24h】

Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. [Review]

机译:代谢组学在肾脏疾病研究中的应用:从生物标志物到治疗靶标。 [评论]

获取原文
获取原文并翻译 | 示例
           

摘要

Metabolomics is one of the relative newcomers of the omics techniques and is likely the one most closely related to actual real-time disease pathophysiology. Hence, it has the power to yield not only specific biomarkers but also insight into the pathophysiology of disease. Despite this power, metabolomics as applied to kidney disease is still in its early adolescence and has not yet reached the mature stage of clinical application, i.e., specific biomarker and therapeutic target discovery. On the other hand, the insight gained from hints into what makes these diseases tick, as is evident from the metabolomics pathways which have been found to be altered in kidney cancer, are now beginning to bear fruit in leading to potential therapeutic targets. It is quite likely that, with greater numbers of clinical materials and with more investigators jumping into the field, metabolomics may well change the course of kidney disease research.Registry Number/Name of Substance 0 (Biological Markers).
机译:代谢组学是组学技术中相对较新的一种,很可能与实际的实时疾病病理生理学密切相关。因此,它不仅具有产生特定生物标志物的能力,而且还具有对疾病病理生理学的洞察力。尽管具有这种能力,但用于肾脏疾病的代谢组学仍处于青春期早期,尚未达到临床应用的成熟阶段,即特定的生物标志物和治疗靶标的发现。另一方面,从暗示使这些疾病发生的原因中获得的见解,如已从在肾脏癌中被改变的代谢组学途径所证明的那样,现已开始在导致潜在的治疗靶点上结出硕果。随着越来越多的临床资料和越来越多的研究人员进入该领域,代谢组学很可能会改变肾脏疾病的研究过程。登记号/物质0的名称(生物标记)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号